Analysts understand the likelihood of success ties directly to a discount rate in valuing early-stage IP. With that in mind, Mike Pellegrino shared with BVR some FDA statistics that readers will find sobering.
Drugs targeting this disease group Experience this success rate
central nervous system 14.5%
infectious disease 28.1%
The new edition to Mike Pellegrino’s Guide to Intellectual Property Valuation is discussed here.